AMENDMENTS

Please amend the claims as follows.

1. (withdrawn) A process for producing a target delivery molecule, which comprises:

(a) synthesizing a target molecule complex comprising (a') a bridging agent selected from the group consisting of a transition element, an inner transition element, a neighbor element of said transition element and a mixture of any of the foregoing elements; and (b') a complexing agent; provided that when said transition element is chromium a chromium target molecule complex is synthesized; and

(b) combining said target molecule into a liposomal matrix to form the target delivery molecule.

2. (withdrawn) The process as defined in claim 1 wherein steps (a) and (b) are simultaneously carried out in situ.

3. (withdrawn) The process of claim 1, wherein said liposomal matrix comprises a charged liposomal structure.

4. (withdrawn) The process of claim 1, wherein said chromium target molecule complex is prepared by a method comprising

(a) combining an aqueous solution of N-(2,6-diisopropylphenylcarbamoylmethyl) iminodiacetic acid having a pH between 3.2 and 3.3 with an aqueous solution of a chromium compound having a pH between 4.0 and 4.4 to form a reaction solution;

(b) maintaining the reaction solution at a pH between 3.2 and 3.3 to form a complex solution; and

(c) incubating said complex solution to form said chromium complex.

5. (currently amended) An hepatocyte-specific target delivery molecule comprising a synthesized water insoluble target molecule complex, wherein said complex comprises multiple linked individual units and a liposome matrix, said multiple linked individual units comprising: a bridging component agent selected from the group consisting of a transition element, an inner transition element, a neighbor element of said transition element and a mixture of any of the foregoing elements, and a complexing component agent, provided that when said transition element is chromium, a chromium target molecule complex is created, in combination with a liposome matrix. Wwherein said multiple linked individual units are combined with said liposome matrix.

6. (withdrawn) The process of claim 1 which further comprises the step of combining a pharmacological agent with the target delivery molecule to form a pharmacological delivery system.

7. (currently amended) A The hepatocyte-specific target delivery system comprising the hepatocyte-specific target delivery molecule of claim 5, and wherein a pharmacological, therapeutic, or diagnostic agent is combined with said target delivery molecule to form an hepatocyte-specific targeted delivery.

8. (currently amended) The hepatocyte-specific targeted delivery system of claim 7, wherein said pharmacological, therapeutic, or diagnostic agent is sequestered by the liposome matrix or entrapped in the liposomal core volume or associated with said the liposome matrix surface or is otherwise captured by the liposome through the utilization of combinations of these sequestering means.

9. (previously presented) The hepatocyte-specific targeted delivery system of claim 7, wherein said pharmacological agent comprises insulin or a derivative thereof.

10. (previously presented) The hepatocyte-specific targeted delivery system of claim 7, wherein said pharmacological agent comprises serotonin or a serotoninergic agent.

11. (currently amended) The hepatocyte-specific targeted delivery system of claim 7, wherein said liposome matrix comprises a lipid selected from the group consisting of distearoyl lecithin, cholesterol, ~~and~~ dicetyl phosphate, and a mixture of any of the foregoing lipids.

12. (canceled)

13. (currently amended) The hepatocyte-specific ~~targeting~~ target delivery molecule of claim 5, wherein said bridging component is chromium ~~comprising~~

~~(a) a liposomal membrane; and~~

~~(b) a target complex comprising (a') a bridging element or a dissociated moiety thereof or a water-insoluble polynuclear complex or a mixture of the foregoing, where said dissociated moiety exists with or without metal in the liposome membrane; and (b') a complexing agent; provided that when said bridging element is chromium a chromium target molecule complex as shown in Figure 2 is present in the hepatocyte targeting molecule.~~

14. (currently amended) The hepatocyte-specific ~~targeting~~ target delivery molecule of claim ~~13~~ 5, wherein said complexing component ~~agent~~ comprises N-(2,6-diisopropylphenylcarbamoylmethyl) iminodiacetic acid.

15. (currently amended) The hepatocyte-specific ~~targeting~~ target delivery molecule of claim ~~13~~ 5, wherein said liposome matrix ~~liposomal membrane~~ comprises a lipid selected from the group consisting of distearoyl lecithin, cholesterol, dicetyl phosphate, and a mixture of the foregoing lipids.

16. (currently amended) The hepatocyte-specific targeting molecule of claim 15, wherein said lipid ~~liposomal membrane~~ comprises a mixture of distearoyl lecithin, cholesterol and dicetyl phosphate.

17. (currently amended) The hepatocyte-specific targeting molecule of claim 16, wherein said distearoyl lecithin is present in an amount of about 25.5 micro moles/ml, said cholesterol is

present in an amount of about 6.85 micro moles/ml and said dicetyl phosphate is present in an amount of about 9.4 micro moles/ml with 0.465 micro moles/ml of chromium complex.

18. (currently amended) An article of manufacture for delivering an agent in liposome form to ~~the~~ hepatocytes in the liver, said article comprising a water insoluble chromium target molecule complex or a dissociated moiety thereof and a liposome matrix, wherein said target molecule complex comprises multiple linked individual units, said multiple linked individual units comprising a chromium bridging component and at least one complexing component or a mixture of complexing components, wherein said target molecule complex is soluble in said liposome matrix, is specific for cellular hepatocytes, and is soluble in organic solvents. ~~Containing first member comprising a chromium target molecule complex or a dissociated moiety thereof, said first member being soluble in a second member comprising a liposome which is capable of carrying the agent, wherein said first member is specific for cellular hepatocytes, exhibits a maximum visible absorption spectrum at 5250 Å, is soluble in organic solvents and has a first structural component which is chromium and a second and a third structural component comprising at least one complexing agent or a mixture of complexing agents~~.

19. (currently amended) The article of manufacture of claim 18, wherein said complexing component ~~agent~~ comprises N-(2,6-diisopropylphenylcarbamoylmethyl)iminodiacetic acid.

20. (currently amended) The article of manufacture of claim 18, wherein said ~~the~~ agent comprises a therapeutic agent.

21. (currently amended) The article of manufacture of claim 18, wherein said ~~the~~ agent comprises a diagnostic agent.

22. (currently amended) A liposomal delivery system directed to hepatocytes of a warm-blooded host, said liposomal delivery system comprising a liposome, at least one water insoluble target molecule complex and an active agent, wherein said target molecule complex comprises multiple linked individual units, wherein said target molecule complex is soluble in said

liposome, and wherein said active agent is associated with said liposome for delivery of said agent to said hepatocytes ~~at least one bridging agent complex which is insoluble in water and soluble in said liposome and an active agent destined to be delivered to the hepatocytes which is carried by said liposome~~.

23. (currently amended) The system of claim 22, wherein said active agent is a therapeutic agent.

24. (currently amended) The system of claim 22, wherein said active agent is a diagnostic agent.

25. (currently amended) The system of claim 22, wherein said target molecule ~~bridging agent~~ complex comprises a chromium target molecule complex or a dissociated form thereof.

26. (currently amended) The system of claim 25, wherein said chromium target molecule complex is complexed with N-(2,6-diisopropylphenylcarbamoylmethyl)iminodiacetic acid.

27. (currently amended) The system of claim 22, wherein said active agent is insulin or a derivative thereof.

28. (currently amended) The system of claim 22, wherein said active agent comprises an insulin derivative, said derivative comprising ~~being composed of~~ a single or several combinations of monomeric insulin subunits ranging in composition from one monomeric subunit to nine associated monomeric subunits or a combination thereof, wherein at least one of said derivatives is associated with said liposome ~~preferentially loads into the core or into the membrane or onto the surface of said liposome for delivery to the hepatocytes in the liver of a warm blooded host~~.

29. (withdrawn) A process for producing a hepatocyte directed vesicle comprising the steps of:

(a) reacting chromium with N-(2,6-diisopropylphenylcarbamoylmethyl)iminodiacetic acid to form a chromium target molecule complex, and

(b) adding the chromium target molecule complex to a liposome to form the hepatocyte directed vesicle.

30. (canceled)

31. (withdrawn) A process for producing a hepatocyte directed vesicle comprising the steps of:

(a) reacting a suitable metal selected from a transition metal other than chromium, an inner transition metal, a neighbor metal of said transition metal and a mixture of any of the foregoing metals with a suitable complexing agent to form a target molecule complex; and

(b) adding said complex to a liposome to form a hepatocyte directed vesicle.

32. (currently amended) A composition for delivering an active agent to a target site in a mammal, wherein said composition comprises a hepatocyte-specific target delivery molecule comprising a water insoluble target molecule complex, wherein said complex comprises multiple linked individual units and a liposome matrix, said multiple linked individual units comprising: a bridging component selected from the group consisting of a transition element, an inner transition element, a neighbor element of said transition element and a mixture of any of the foregoing elements, and a complexing component, provided that when said transition element is chromium, a chromium target molecule complex is created, wherein said multiple linked individual units are combined with said liposome matrix. ~~which comprises, a transport agent comprising a liposome having associated therewith a bridging agent selected from a metal complex, a dissociated form thereof or a water insoluble polynuclear complex or a mixture of any of the foregoing; where said dissociated form exists with or without metal present in said liposome; provided that when compound chromium is used, it is present as a chromium target molecule complex or a dissociated form thereof~~.

33. (currently amended) The composition of ~~as defined in~~ claim 32, wherein said liposome matrix comprises a lipid selected from the group consisting of distearoyl lecithin, cholesterol, dicetylphosphate and a mixture of any of the foregoing lipids.

34. (currently amended) The composition of ~~as defined in~~ claim 33 ~~32~~, wherein said lipid ~~liposome~~ comprises a mixture of distearoyl lecithin, cholesterol, and dicetyl phosphate.

35. (currently amended) The composition of ~~as defined in~~ claim 32, ~~which~~ further comprising ~~comprises~~ an active agent associated with said liposome matrix.

36. (currently amended) The composition as defined in claim 35, wherein said active agent is selected from the group consisting of insulin, a derivative thereof, and ~~or~~ serotonin.

37. (withdrawn) A chromium complex which is prepared by a method comprising

(a) combining an aqueous solution of N-(2,6-diisopropylphenylcarbamoylmethyl) iminodiacetic acid having an pH between 3.2 and 3.3 with an aqueous solution of a chromium compound having a pH between 4.0 and 4.4 to form a reaction solution;

(b) maintaining the reaction solution at a pH between 3.2 and 3.3 to form a complex solution; and

(c) incubating said complex solution to form the chromium complex.

38. (withdrawn) The complex of claim 37, wherein said chromium compound is chromium (III) chloride hexahydrate.

39. (withdrawn) A water-insoluble hepatocyte targeting complex comprising chromium (bis)[N-(2,6-diisopropylphenylcarbamoylmethyl)iminodiacetic acid].

40. (withdrawn) An organic soluble chromium target molecule complex formed by combining N-(2,6-diisopropylphenylcarbamoylmethyl)iminodiacetic acid and chromium (III)

chloride which demonstrates targeting ability for the hepatocytes of the liver in a warm-blooded host.

41. (withdrawn) The complex of claim 40 wherein an atom of chromium is bound to two molecules of said iminodiacetic acid and is insoluble in aqueous media.

42. (canceled)

43. (canceled)

44. (canceled)

45. (canceled)

46. (canceled)

47. (canceled)

48. (canceled)

Respectfully Submitted,

W. BLAIR GEHO ET AL.

February 9, 2006
(Date)

By: Kathryn Doyle

KATHRYN DOYLE, Ph.D., J.D.
Registration Number: 36,317
Drinker Biddle & Reath LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
Direct Telephone: 215-988-2902
Facsimile: 215-988-2757
E-Mail: Kathryn.Doyle@dbr.com